+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Future of Multiple System Atrophy (MSA) R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

  • ID: 4749279
  • Report
  • February 2019
  • Region: Global
  • 50 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • AFFiRiS AG
  • Corestem Inc
  • Denali Therapeutics Inc
  • Enterin Inc
  • ICB International Inc
  • Inhibikase Therapeutics
  • MORE
The global demand for Multiple System Atrophy (MSA) treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Multiple System Atrophy (MSA) pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Multiple System Atrophy (MSA) pipeline companies from advancing their products into Phase 3 or Phase 4.

Multiple System Atrophy (MSA) Report Description

The 2019 pipeline study on Multiple System Atrophy (MSA) pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Multiple System Atrophy (MSA) pipeline compounds.

The Multiple System Atrophy (MSA) pipeline guide presents information on all active drugs currently being developed for Multiple System Atrophy (MSA). The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Multiple System Atrophy (MSA) pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Multiple System Atrophy (MSA) drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Multiple System Atrophy (MSA) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Multiple System Atrophy (MSA) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

The publisher has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Multiple System Atrophy (MSA) pipeline report includes
  • An overview of Multiple System Atrophy (MSA) disease including symptoms, causes, diagnosis and available treatment options is provided.
  • Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
  • Phase wise count of Multiple System Atrophy (MSA) pipeline
  • Company wise list of Multiple System Atrophy (MSA) pipeline
  • Mechanism of Action wise Multiple System Atrophy (MSA) pipeline
For each pipeline candidate, the following details are provided:
  • Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
  • Current status of development
  • Drug overview
  • Mechanism of Action
  • Pre-clinical and Clinical Trials/Results
  • Company Overview and Recent Developments
Reasons to Buy
  • The report is designed to help industry executives promote the success and continued growth of their organizations
  • Get clear understanding of the entire Multiple System Atrophy (MSA) pipeline, with details on active projects
  • Stay ahead of the competition through comprehensive knowledge of Multiple System Atrophy (MSA) pipeline progress
  • Get in detail information of each product with updated information on each project along with key milestones
  • Gain clear insights into companies participating in Multiple System Atrophy (MSA) pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
The report will be delivered in 2 working days.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AFFiRiS AG
  • Corestem Inc
  • Denali Therapeutics Inc
  • Enterin Inc
  • ICB International Inc
  • Inhibikase Therapeutics
  • MORE
1.1 List of Tables
1.2 List of Figures

2. Global Multiple System Atrophy (MSA) Pipeline Overview
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology

3. Executive Summary
3.1 Multiple System Atrophy (MSA) Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
3.2.1 Pre-clinical
3.2.2 Discovery
3.2.3 Phase 1
3.2.4Phase 2
3.3 Pipeline Drugs in Advanced Stage of Development
3.3.1 Phase 3
3.3.2 Pre-registration
3.4 Companies involved in Multiple System Atrophy (MSA) pipeline, H1- 2019
3.5 Mechanism of Action wise Multiple System Atrophy (MSA) Pipeline Candidates

4 AFFiRiS AG Multiple System Atrophy (MSA)/Shy-Drager Syndrome Pipeline Details
4.1 AFFiRiS AG Business Profile
4.2 AFFiRiS AG Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
4.3 Drug Snapshot
4.3.1 Originator
4.3.2 Collaborator/Co-Developer
4.3.3 Route of Administration
4.3.4 Orphan Drug/Fast Track/Special Designation
4.3.5 Geography
4.3.6 Type of Molecular Entity
4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5 Biohaven Pharmaceutical Holding Company Multiple System Atrophy (MSA)/Shy-Drager Syndrome Pipeline Details
5.1 Biohaven Pharmaceutical Holding Company Business Profile
5.2 Biohaven Pharmaceutical Holding Company Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
5.3 Drug Snapshot
5.3.1 Originator
5.3.2 Collaborator/Co-Developer
5.3.3 Route of Administration
5.3.4 Orphan Drug/Fast Track/Special Designation
5.3.5 Geography
5.3.6 Type of Molecular Entity
5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6 Corestem Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Pipeline Details
6.1 Corestem Inc Business Profile
6.2 Corestem Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
6.3 Drug Snapshot
6.3.1 Originator
6.3.2 Collaborator/Co-Developer
6.3.3 Route of Administration
6.3.4 Orphan Drug/Fast Track/Special Designation
6.3.5 Geography
6.3.6 Type of Molecular Entity
6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7 Denali Therapeutics Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Pipeline Details
7.1 Denali Therapeutics Inc Business Profile
7.2 Denali Therapeutics Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
7.3 Drug Snapshot
7.3.1 Originator
7.3.2 Collaborator/Co-Developer
7.3.3 Route of Administration
7.3.4 Orphan Drug/Fast Track/Special Designation
7.3.5 Geography
7.3.6 Type of Molecular Entity
7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8 Enterin Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Pipeline Details
8.1 Enterin Inc Business Profile
8.2 Enterin Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
8.3 Drug Snapshot
8.3.1 Originator
8.3.2 Collaborator/Co-Developer
8.3.3 Route of Administration
8.3.4 Orphan Drug/Fast Track/Special Designation
8.3.5 Geography
8.3.6 Type of Molecular Entity
8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9 ICB International Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Pipeline Details
9.1 ICB International Inc Business Profile
9.2 ICB International Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
9.3 Drug Snapshot
9.3.1 Originator
9.3.2 Collaborator/Co-Developer
9.3.3 Route of Administration
9.3.4 Orphan Drug/Fast Track/Special Designation
9.3.5 Geography
9.3.6 Type of Molecular Entity
9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments

10 Inhibikase Therapeutics Multiple System Atrophy (MSA)/Shy-Drager Syndrome Pipeline Details
10.1 Inhibikase Therapeutics Business Profile
10.2 Inhibikase Therapeutics Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
10.3 Drug Snapshot
10.3.1 Originator
10.3.2 Collaborator/Co-Developer
10.3.3 Route of Administration
10.3.4 Orphan Drug/Fast Track/Special Designation
10.3.5 Geography
10.3.6 Type of Molecular Entity
10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments

11 MitoDys Therapeutics Ltd Multiple System Atrophy (MSA)/Shy-Drager Syndrome Pipeline Details
11.1 MitoDys Therapeutics Ltd Business Profile
11.2 MitoDys Therapeutics Ltd Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
11.3 Drug Snapshot
11.3.1 Originator
11.3.2 Collaborator/Co-Developer
11.3.3 Route of Administration
11.3.4 Orphan Drug/Fast Track/Special Designation
11.3.5 Geography
11.3.6 Type of Molecular Entity
11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments

12 Modag GmbH Multiple System Atrophy (MSA)/Shy-Drager Syndrome Pipeline Details
12.1 Modag GmbH Business Profile
12.2 Modag GmbH Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
12.3 Drug Snapshot
12.3.1 Originator
12.3.2 Collaborator/Co-Developer
12.3.3 Route of Administration
12.3.4 Orphan Drug/Fast Track/Special Designation
12.3.5 Geography
12.3.6 Type of Molecular Entity
12.3.7 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments

13 Neuropore Therapies Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Pipeline Details
13.1 Neuropore Therapies Inc Business Profile
13.2 Neuropore Therapies Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
13.3 Drug Snapshot
13.3.1 Originator
13.3.2 Collaborator/Co-Developer
13.3.3 Route of Administration
13.3.4 Orphan Drug/Fast Track/Special Designation
13.3.5 Geography
13.3.6 Type of Molecular Entity
13.3.7 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments

14 Prana Biotechnology Ltd Multiple System Atrophy (MSA)/Shy-Drager Syndrome Pipeline Details
14.1 Prana Biotechnology Ltd Business Profile
14.2 Prana Biotechnology Ltd Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
14.3 Drug Snapshot
14.3.1 Originator
14.3.2 Collaborator/Co-Developer
14.3.3 Route of Administration
14.3.4 Orphan Drug/Fast Track/Special Designation
14.3.5 Geography
14.3.6 Type of Molecular Entity
14.3.7 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments

15 United Neuroscience Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Pipeline Details
15.1 United Neuroscience Inc Business Profile
15.2 United Neuroscience Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
15.3 Drug Snapshot
15.3.1 Originator
15.3.2 Collaborator/Co-Developer
15.3.3 Route of Administration
15.3.4 Orphan Drug/Fast Track/Special Designation
15.3.5 Geography
15.3.6 Type of Molecular Entity
15.3.7 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments

16. Latest Multiple System Atrophy (MSA) Drug Pipeline Developments, 2019

17. Appendix
17.1 About Us
17.2 Sources and Methodology
17.3 Contact Information
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AFFiRiS AG
  • Biohaven Pharmaceutical Holding Company
  • Corestem Inc
  • Denali Therapeutics Inc
  • Enterin Inc
  • ICB International Inc
  • Inhibikase Therapeutics
  • MitoDys Therapeutics Ltd
  • Modag GmbH
  • Neuropore Therapies Inc
  • Prana Biotechnology Ltd
  • United Neuroscience Inc
Note: Product cover images may vary from those shown
Adroll
adroll